Impact of Transplant Eligibility on Treatment Selection

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Panelists discuss how transplant eligibility significantly influences first-line treatment goals and initial therapy selection in multiple myeloma, often leading to more intensive induction regimens aimed at achieving deep remissions.

EP: 1.Treatment Landscape for Transplant-Eligible Patients with NDMM

EP: 2.Frontline Treatment and Sequencing Therapy

Now Viewing

EP: 3.Impact of Transplant Eligibility on Treatment Selection

EP: 4.Treatment Regimen Considerations

EP: 5.Impact of IFM 2009 and DETERMINATION Studies

EP: 6.Key End Points in Clinical Trials

EP: 7.Real-World Considerations for New Therapies

EP: 8.Challenges in Adopting Novel Therapies

EP: 9.Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

EP: 10.Impact of SC Daratumumab

EP: 11.SC vs IV Administration Methods

EP: 12.Pharmacists’ Roles in MM Management

EP: 13.Pharmacists’ Roles on the Multidisciplinary Team

EP: 14.Personalizing Treatments and Patient Education

EP: 15.Addressing Payer Coverage Challenges

EP: 16.Unmet Needs for Transplant-Eligible NDMM

EP: 17.Final Thoughts

Video content above is prompted by the following:

How does transplant eligibility impact first-line treatment goals and selection of initial therapy?

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!